Sudeep Pharma Ltd

Sudeep Pharma Ltd share price inched up 0.10% to Rs 869.45. The Company's net profit fell 16.38% to Rs 40.59 crore, while revenue from operations reduced 13.20% to Rs 158.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 6.18%. It has improved by 0.41% over last one week and rose by 11.45% in last one month while the market capitalization of Sudeep Pharma Ltd has softened by 1.06% and 29.50% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 54.29 crore in Q2 FY26, rallying 23.19% year-on-year, and dropping 13.40% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 27.77% YoY and falling 11.95% sequentially. Total expenses reduced by 13.16% to Rs 107.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 68.81 crore, slightly declining by 3.28% YoY, while employee benefits expense was at Rs 14.34 crore, witnessing a strong rise of 36.31% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 27.94% to Rs 642.26 crore, while net profit soared by 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA surged by 18384% to Rs 193.31 crore, and PBT surged 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd jumped 12.38% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.

Sudeep Pharma Ltd share price inched up 0.10% to Rs 869.45. The Company's net profit contracted by 16.38% to Rs 40.59 crore, while revenue from operations declined 13.20% to Rs 158.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, easing 6.21%. It has improved by 1.69% over last one week and rose by 11.78% in last one month while the market capitalization of Sudeep Pharma Ltd has marginally improved by 0.85% and 28.91% in the same period respectively. Profit before tax (PBT) of Sudeep Pharma Ltd stood at Rs 54.29 crore in Q2 FY26, expanding by 23.19% year-on-year, and dropping 13.40% quarter-on-quarter. EBITDA came in at Rs 49 crore, rallying 27.77% YoY and falling 11.95% sequentially. Total expenses reduced by 13.16% to Rs 107.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 68.81 crore, softening by 3.28% YoY, while employee benefits expense was at Rs 14.34 crore, soaring 36.31% YoY. For the TTM ended FY26, revenue from operations surged 27.94% to Rs 642.26 crore, while net profit soared by 25.63% to Rs 174.28 crore, compared to previous TTM. EBITDA surged by 18384% to Rs 193.31 crore, and PBT soared 24.73% to Rs 228.07 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 69.55 crore in FY26, as against Rs 48.73 crore in FY25. Sudeep Pharma Ltd jumped 12.26% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Sudeep Pharma announced that the 37th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Sudeep Pharma announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 150%) , subject to the approval of the shareholders.

Net profit of Sudeep Pharma rose 10.61% to Rs 48.88 crore in the quarter ended March 2026 as against Rs 44.19 crore during the previous quarter ended March 2025. Sales rose 15.73% to Rs 182.34 crore in the quarter ended March 2026 as against Rs 157.55 crore during the previous quarter ended March 2025. For the full year,net profit rose 24.62% to Rs 172.89 crore in the year ended March 2026 as against Rs 138.73 crore during the previous year ended March 2025. Sales rose 27.94% to Rs 642.26 crore in the year ended March 2026 as against Rs 502.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales182.34157.55 16 642.26502.00 28 OPM %34.3337.31 -34.5537.84 - PBDT66.5860.68 10 242.88193.44 26 PBT62.6957.85 8 228.07182.85 25 NP48.8844.19 11 172.89138.73 25 Powered by Capital Market - Live

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2026.

Net profit of Sudeep Pharma rose 65.31% to Rs 47.46 crore in the quarter ended December 2025 as against Rs 28.71 crore during the previous quarter ended December 2024. Sales rose 49.16% to Rs 172.34 crore in the quarter ended December 2025 as against Rs 115.54 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales172.34115.54 49 OPM %34.8034.01 - PBDT65.6440.32 63 PBT61.7837.66 64 NP47.4628.71 65 Powered by Capital Market - Live

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 19 December 2025.Powered by Capital Market - Live